Roche: new positive data for fenebrutinib
(CercleFinance.com) - Roche announces that it will present new positive 48-week data for fenebrutinib from the FENopta phase II open-label extension study at the ECTRIMS congress in Copenhagen on 18 September.
The results show that patients with relapsing-remitting multiple sclerosis (RRMS) treated with fenebrutinib for up to a year maintained very low levels of disease activity and no progression of disability.
The Swiss healthcare group adds that the product's safety profile has been consistent with previous and ongoing multi-disease clinical trials, involving over 2,700 people to date.
Three Phase III clinical trials are underway with fenebrutinib, including the FENhance 1 and 2 trials in RRMS and the FENtrepid trial in primary progressive multiple sclerosis. Data from these studies are expected by the end of 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The results show that patients with relapsing-remitting multiple sclerosis (RRMS) treated with fenebrutinib for up to a year maintained very low levels of disease activity and no progression of disability.
The Swiss healthcare group adds that the product's safety profile has been consistent with previous and ongoing multi-disease clinical trials, involving over 2,700 people to date.
Three Phase III clinical trials are underway with fenebrutinib, including the FENhance 1 and 2 trials in RRMS and the FENtrepid trial in primary progressive multiple sclerosis. Data from these studies are expected by the end of 2025.
Copyright (c) 2024 CercleFinance.com. All rights reserved.